Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.60 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.60 |
| ▸ | KYNU | Q16719 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664902 | 1.00 | SIRT2 (0.60) | SIRT2SIRT1SIRT3KYNUALDH1A1 | |
| SCHEMBL2156000 | 0.95 | KYNU (0.58) | SIRT2SIRT1SIRT3KYNUALDH1A1 | |
| SCHEMBL2155610 | 0.95 | KYNU (0.58) | SIRT2SIRT1SIRT3KYNUALDH1A1 | |
| SCHEMBL15665249 | 0.91 | SIRT2 (0.56) | SIRT2SIRT1SIRT3KYNUALDH1A1 | |
| SCHEMBL18762518 | 0.90 | SIRT2 (0.57) | SIRT2SIRT1CTSLCTSS | |
| SCHEMBL15666217 | 0.90 | SIRT2 (0.57) | SIRT2SIRT1CTSLCTSS | |
| SCHEMBL15666216 | 0.90 | SIRT2 (0.57) | SIRT2SIRT1CTSLCTSS | |
| SCHEMBL8386880 | 0.90 | SIRT2 (0.67) | SIRT2SIRT1SIRT3KYNUALDH1A1 | |
| SCHEMBL8065343 | 0.86 | SIRT2 (0.56) | SIRT2SIRT1SIRT3KYNUALDH1A1 | |
| SCHEMBL15665178 | 0.86 | KYNU (0.55) | SIRT2SIRT1SIRT3KYNUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914596-B1 | HYDROXY SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20160176880-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176880-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176880-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| WO-2015018808-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-12 | — | — | WO | disclosed |
| US-8946215-B2 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946215-B2 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946215-B2 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8778964-B2 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8778964-B2 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8778964-B2 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176880-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | AADAC, PAICS, TPMT | SIRT2 89/4885SIRT1 104/4885SIRT3 178/4885 |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAH | SIRT2 66/4885SIRT1 52/4885SIRT3 26/4885 |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | TNNI3, AADAC, TNNT2 | SIRT2 82/4885SIRT1 68/4885SIRT3 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.